Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Tonix Pharma ( (TNXP) ) has provided an announcement.
On April 28, 2025, Tonix Pharmaceuticals presented promising data at the AACR Annual Meeting, demonstrating that their fusion protein mTFF2-MSA, combined with an anti-PD1 antibody, effectively activates cancer-killing CD8+ T Cells and reduces immunosuppression in tumor microenvironments in animal models. This development highlights Tonix’s potential impact in cancer treatment, particularly with their TNX-1700 candidate, which is in preclinical stages for gastric and colorectal cancers.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score reflects a growth phase with substantial revenue increases and strategic advancements in product development. However, the company faces significant profitability challenges and reliance on external funding, impacting financial sustainability. Positive corporate events provide some optimism, yet technical indicators remain weak, capping the overall score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing innovative therapies for various conditions. The company is currently working on TNX-1700, a product candidate in preclinical development aimed at treating gastric and colorectal cancers.
YTD Price Performance: -48.36%
Average Trading Volume: 1,588,492
Technical Sentiment Signal: Strong Buy
Current Market Cap: $117.1M
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.